Sign In
Buy BIO
$301.90
-2.46 (-0.81%)
At Close: Jul 20, 2026
BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
04:15pm, Monday, 30'th Mar 2026
KUALA LUMPUR, MALAYSIA, March 30, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. ("BGMS," the "Company" or “we,” formerly Cyclacel Pharmaceuticals, Inc.) (NASDAQ: BGMS), a diversified compa
Identity and Biometric Authentication Cybersecurity Provider BIO-key to Host Year-End Investor Call Tuesday, March 31st at 10am ET
07:58am, Wednesday, 25'th Mar 2026
BKYI: Identity and Biometric Authentication Cybersecurity Provider BIO-key to Host Year-End Investor Call Tues., Mar 31 at 10am ET. Dial-in: 1-877-418-5460
Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
08:00am, Tuesday, 24'th Mar 2026
AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced toda
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
04:58pm, Wednesday, 18'th Mar 2026
BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company,
BIO-key Partners with TD SYNNEX Public Sector (DLT) to Deliver Identity-Bound Biometric and IAM Solutions to the U.S. Public Sector
07:57am, Thursday, 12'th Mar 2026
HOLMDEL, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions enablin
Fisher Asset Management LLC Lowers Stock Position in Bio-Rad Laboratories, Inc. $BIO
04:20am, Wednesday, 04'th Mar 2026
Fisher Asset Management LLC trimmed its stake in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 3.1% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 133,465 s
Retail Bank Executes Expanded $1.04M License Renewal for BIO-key Biometric Identity Solution Serving 30M Clients
04:01am, Tuesday, 03'rd Mar 2026
Retail Bank Executes Expanded $1.04M License Renewal for BIO-key Biometric Identity Solution Serving 30M Clients, cash position provides base for growth.
FibroBiologics to Present at the BIO Investment & Growth Summit
08:30am, Thursday, 26'th Feb 2026
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the d
International Markets and Bio-Rad (BIO): A Deep Dive for Investors
10:16am, Friday, 20'th Feb 2026
Examine Bio-Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down
09:36am, Thursday, 19'th Feb 2026
BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Recommendation of “Hold” by Brokerages
03:29am, Thursday, 19'th Feb 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO - Get Free Report) has earned a consensus recommendation of "Hold" from the six research firms that are covering the stock, Marketbeat reports. One investment ana
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
07:34pm, Thursday, 12'th Feb 2026
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
Bio-Rad Laboratories (BIO) Q4 Earnings Miss Estimates
06:35pm, Thursday, 12'th Feb 2026
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago.
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
04:15pm, Thursday, 12'th Feb 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t
Allianz Asset Management GmbH Boosts Position in Bio-Rad Laboratories, Inc. $BIO
03:30am, Saturday, 07'th Feb 2026
Allianz Asset Management GmbH raised its holdings in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 22.7% during the undefined quarter, according to its most recent disclosure with the Securities and Excha
